Abstracts tagged "rheumatologic adverse events and co-medications"

Abstract Number: 1811 • ACR/ARP Annual Meeting 2019
Commonly Used Drugs in Rheumatology May Alter Anti-Tumoral Response to Immune Checkpoint Inhibitors
Marie Kostine¹, Eleonora Mauric ², Thomas Barnetche ³, Léa Rouxel ³, Caroline Dutriaux ⁴, Léa Dousset ⁴, Sorilla Prey ⁴, Marie Beylot-Barry ⁴, Julien Seneschal ⁵, Rémi Veillon ⁶, Vergnenegre Charlotte ⁶, Amaury Daste ⁷, Domblides Charlotte ⁷, Baptiste Sionneau ⁷, Marine Gross-Goupil ⁷, Alain Ravaud ⁷, Edouard Forcade ⁸, Bernard Bannwarth ³, Nadia Mehsen-Cetre ³, Marie-Elise Truchetet ⁹, Christophe Richez ¹⁰ and Thierry Schaeverbeke ³, ¹Department of Rheumatology, Bordeaux, France, ²FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁴FHU ACRONIM, Department of Dermatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁵department of dermatology, centre hospitalier universitaire de Bordeaux, BORDEAUX, France, ⁶Department of Pneumology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁷Department of Oncology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁸Department of Hematology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁹FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France. Bordeaux University, CNRS 5164, 33000 Bordeaux, France, Bordeaux, France, ¹⁰Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICIs) are revolutionizing the treatment of some advanced cancers. Gut microbiota has emerged as an important component of anti-tumoral response and…